TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03858582

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: 52.8Gy/24Fx or 59.4Gy/27Fx
Study: NCT01096329

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrinsa® Patch and Testosterone Spray 5%
Description: Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrinsa® Patch and Testosterone Spray 1%
Description: Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
Study: NCT03797703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine Hydrochloride 2% gel enema
Description: Insertion of Lidocaine Hydrochloride 2% gel enema rectally immediately following the procedure.
Study: NCT00669331

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matched control
Description: 50mg dose of Mannitol BD (twice a day) for 52 weeks
Study: NCT02429739

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Working memory Training
Description: The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.~Other name: Cogmed RoboMemo
Study: NCT04116957

Intervention type: DEVICE
Group type: OTHER
Intervention: RTLS current tag
Description: Validate location system performance against manual observation of nursing activity

Intervention type: DEVICE
Group type: OTHER
Intervention: RTLS tag revised
Description: Test a next-generation RTLS tag for healthcare process validation
Study: NCT04219306

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alert on dispatchers screen 'Suspect cardiac arrest'
Description: Alert on dispatchers screen 'Suspect cardiac arrest'
Study: NCT04092036

Intervention type: DEVICE
Intervention: Optic Nerve Sheath Diameter (ONSD) measurement by ultrasound
Description: ONSD measurements will be performed in the supine patient. Ultrasound gel will be applied over the closed upper eyelid. The ultrasound probe will be placed on the temporal area of the eyelid. Then the probe will be angled in order to display the entry of the optic nerve into the globe.~ONSD will be measured 3 mm behind the globe in the transverse plane perpendicular to the optic nerve. For each optic nerve three measurements will be made. The ONSD corresponds to the mean of the six values which will be obtained from each patient (three measurements for each eye).
Study: NCT03667651

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EpiCeram
Description: Parents will be instructed to apply EpiCeram™ to the full skin surface of their child twice per day for six months.
Study: NCT03708692

Intervention type: BEHAVIORAL
Intervention: Group F
Description: After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.

Intervention type: BEHAVIORAL
Intervention: Group F
Description: After general anesthesia, the time of return of the behaviors such as opening the eyes, fulfilling the orders or saying the age will be recorded and evaluated as the recovery criteria. In the postop recovery period, the patient will be subjected to mini mental state testing (MMST) and cognitive functions will be evaluated.
Study: NCT00920309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care-Placebo
Study: NCT02806427

Intervention type: OTHER
Intervention: Enteral Formula
Study: NCT04985708

Intervention type: OTHER
Intervention: data collection of clinically available procedures
Description: when to place Impella related to PCI in patients with AMICS

Intervention type: OTHER
Intervention: data collection of clinically available procedures
Description: when to place Impella related to PCI in patients with AMICS

Intervention type: OTHER
Intervention: data collection of clinically available procedures
Description: when to place Impella related to PCI in patients with AMICS
Study: NCT02203370

Intervention type: DEVICE
Intervention: NIRS - Near-infrared spectroscopy
Study: NCT02024009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy in 30#

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 60Gy in 30#

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50.4Gy in 28#
Study: NCT02819596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Study: NCT06743061

Intervention type: BEHAVIORAL
Intervention: Post-Op Follow Up
Description: Post Arthroscopic Biceps Tenotomy and Subacromial Decompression in Chronic Massive Rotator Cuff Tears.
Study: NCT04223791

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOR/ISL
Description: 100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DOR/ISL
Description: 100 mg DOR/ 0.75 ISL FDC tablet taken orally once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIC/FTC/TAF
Description: 50 mg BIC, 200 mg FTC, and 25 mg TAF combined in a single tablet, taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to BIC/FTC/TAF
Description: Placebo to BIC/FTC/TAF in a single tablet taken orally, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to FDC DOR/ISL
Description: Placebo to FDC DOR/ISL in a tablet taken orally, once daily
Study: NCT04552990

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jet injection of ALA
Description: The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jet injection of ALA
Description: The Basal Cell Carcinoma/BCC tumor and a 5 mm margin will be injected with a grid of 80 microliters of 20% ALA at 5-8.5 mm between each injection (30-50% overlap).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical excision
Description: In the first 4 patients, the tumor will be excised according to national guidelines after 3h incubation (+/- 30 min is accepted).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Illumination
Description: For patients 5-16,after 3h incubation (+/- 30 min), the tumor will be illuminated with red light corresponding to a dose of 75 J/cm2 570- 670 nm or equivalent dose of narrowband red light. The intervention will be repeated at after 14 days in patient 5-16. If the wound is not healed at two weeks, the treatment may be postponed to allow healing (patient 5-16).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incubation
Description: After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Incubation
Description: After injection of ALA, the tumor will be occluded with a light proof dressing and incubated for 3h (+/- 30 min).
Study: NCT01000961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cystagon® (Cysteamine Bitartrate)
Description: Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cysteamine Bitartrate Delayed-release Capsules (RP103)
Description: Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:~Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks
Study: NCT02024009

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 50.4Gy in 28#
Study: NCT02819596

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Study: NCT03062917

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Bronchial Sampling
Description: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Bronchial Sampling
Description: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Bronchial Sampling
Description: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Bronchial Sampling
Description: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Nasal and Bronchial Sampling
Description: Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
Study: NCT02870673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SHINCORT
Description: triamcinolone Acetonide (10mg/ml) 0.5 ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XYLOCAINE
Description: xylocaine(20mg/ml) 0.5 ml

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham electroacupuncture
Description: 1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: 1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
Study: NCT03509506

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: App Group
Description: The participants will be educated to use the HFHS application to monitor their daily vital signs (HR, BP, body weight), physical activity, and medications for 4 weeks.~The research team will monitor their data entry remotely via the HFHS App. The team will text the participant via the App if one or more of following conditions is noted:~* The vital signs show undesired readings~* The records on the HFHS App show that the participant did not take the medications as the schedule says~In addition, the team will call the participant 3 days later to follow up regarding the participant's action towards the text message that the team sent.
Study: NCT01875224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Belatacept

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Standard administration of tacrolimus
Study: NCT03997578

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: NIPSA (Non-incised papilla surgical approach)
Description: To access the defect, a single horizontal or oblique apical incision will be made in the mucosa located on the bony cortex, far from the marginal tissues and apically to the edge of the bony crest delimiting the defect. The incision will be extended mesiodistally as necessary to allow access to the defect and correct debridement of the granulation tissue. The tissue coronal to the incision will be raised full thickness, trying to maintain the preoperative papillae architecture intact. The granulation tissue and epithelium of the pocket will be eliminated. The affected root will be scaled and planed, and calculus eliminated. Once the defect will be debrided, the regenerative biomaterials will be applied. Then the incision line will be sutured by a double suture line to facilitate closing without tension: The first with internal horizontal mattress sutures to approximate the connective tissue of both edges of the mucosal incision, and the second with single interrupted sutures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: NIPSA plus connective tissue graft
Description: In these patients, the following methodology will be added to the technique described for the NIPSA group: once the biomaterials are applied, a connective tissue graft, taken at the level of the first upper molar, will be sutured to the base of the soft supra-alveolar tissue and to the palatal tissue, which has not been disinserted, using simple sutures.
Study: NCT05304832

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aqua-Plyometric Exercise
Description: The aqua-plyometric training was conducted for 45 minutes, twice weekly, for 12 successive weeks. The training was geared toward the lower body and was conducted under close supervision of a licensed pediatric physical therapist in accordance with the safety performance guidelines defined by the American Academy of Pediatrics and the US National Strength and Conditioning Association.
Study: NCT04512235

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAEL-101
Description: The investigational product, CAEL-101, is formulated as a sterile liquid solution of protein plus excipients for dilution in a single-use, stoppered, glass vial. Each 10 mL vial contains 300 mg of CAEL-101 at a concentration of 30 mg/mL. CAEL-101 will be diluted with commercially available 0.9% Normal Saline.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Commercially available 0.9% Normal Saline will be used as the placebo.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cyclophosphamide, bortezomib, and dexamethasone (CyBorD) regimen
Description: According to institutional standard of care.
Study: NCT02024009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelfinavir
Description: VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given in combination with gemcitabine, known as GemCap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Given in combination with gemcitabine, known as GemCap.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
Study: NCT01846871

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivozanib
Study: NCT02022527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetyl Salicylic Acid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Aspirin)
Description: Sugar pill manufactured to mimic 75 mg Aspirin
Study: NCT03736369

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DWP14012 40mg
Description: DWP14012 40mg, tablet, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DWP14012 40mg placebo
Description: DWP14012 40mg placebo-matching tablet, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole 40mg
Description: Esomeprazole 40mg tablet, orally, once daily for up to 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40mg placebo
Description: Esomeprazole 40mg placebo-matching tablet, orally, once daily for up to 8 weeks
Study: NCT05244837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg
Description: Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg
Description: Tislelizumab 200mg IV Q3W + Followed by adjuvant treatment for 1 year (Tislelizumab 200 mg IV Q3W for 2 cycles and Tislelizumab 200 mg Q4W for 12 cycles)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5
Description: Carboplatin AUC 5 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin AUC 5
Description: Carboplatin AUC 5 IV Q3W

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed 500mg/m2
Description: Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed 500mg/m2
Description: Pemetrexed 500mg/m2 IV Q3W if non-squamous lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175mg/m2
Description: Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel 175mg/m2
Description: Paclitaxel 175mg/m2 IV Q3W if squamous lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 260 mg/m2
Description: nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel 260 mg/m2
Description: nab-paclitaxel 260 mg/m2 Q3W if squamous lung cancer
Study: NCT04761354

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy
Study: NCT04266197

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
Description: RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
Description: RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Drug: RT234 - vardenafil inhalation powder; Device: Axially Oscillating Sphere dry powder inhaler (AOS DPI)
Description: RT234 capsules of a dry powder formulation containing vardenafil administered via oral inhalation with a non-invasive AOS DPI.
Study: NCT04761354

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy
Study: NCT00829309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin
Description: 80 mg Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pravastatin
Description: 80 mg Tablets
Study: NCT03012529

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifampin
Description: Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
Study: NCT04761354

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy

Intervention type: PROCEDURE
Intervention: Unilateral adrenalectomy
Study: NCT05304832

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard physical therapy
Description: The program encompassed the standard exercises for patients with JIA (aerobic, weight-bearing, proprioceptive, flexibility, and strengthening exercises). The training was conducted for 40 minutes, two times a week for 12 successive weeks.